Sara De Dosso

8.9k total citations · 2 hit papers
57 papers, 3.6k citations indexed

About

Sara De Dosso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Sara De Dosso has authored 57 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Sara De Dosso's work include Colorectal Cancer Treatments and Studies (26 papers), Genetic factors in colorectal cancer (10 papers) and Neuroendocrine Tumor Research Advances (9 papers). Sara De Dosso is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Genetic factors in colorectal cancer (10 papers) and Neuroendocrine Tumor Research Advances (9 papers). Sara De Dosso collaborates with scholars based in Switzerland, Italy and Germany. Sara De Dosso's co-authors include Piercarlo Saletti, Milo Frattini, Francesca Molinari, Luca Mazzucchelli, Alberto Bardelli, Federica Di Nicolantonio, Andrea Sartore‐Bianchi, Miriam Martini, Salvatore Siena and Sabrina Arena and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sara De Dosso

56 papers receiving 3.5k citations

Hit Papers

Wild-Type BRAF Is Required for Response to Panitumumab or... 2008 2026 2014 2020 2008 2009 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
    2008 1.3k citations Federica Di Nicolantonio, Miriam Martini et al. profile →
  2. PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
    2009 601 citations Andrea Sartore‐Bianchi, Miriam Martini et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara De Dosso Switzerland 21 3.0k 1.1k 1.1k 806 777 57 3.6k
Ilhan Celik Germany 15 2.8k 1.0× 1.6k 1.5× 911 0.8× 749 0.9× 605 0.8× 31 3.9k
David Tougeron France 36 2.4k 0.8× 1.4k 1.3× 1.0k 0.9× 489 0.6× 690 0.9× 223 3.9k
O. Kisker Germany 28 2.0k 0.7× 876 0.8× 376 0.3× 988 1.2× 620 0.8× 43 3.3k
Samuel J. Klempner United States 39 3.3k 1.1× 2.2k 2.0× 1.1k 1.0× 1.7k 2.1× 1.3k 1.7× 197 5.4k
Robert Lim Singapore 22 3.1k 1.0× 1.4k 1.2× 351 0.3× 1.3k 1.7× 1.1k 1.4× 56 4.5k
Susana Roselló Spain 31 2.3k 0.8× 1.0k 0.9× 603 0.5× 885 1.1× 859 1.1× 89 3.6k
Zhongwu Li China 30 1.7k 0.6× 969 0.9× 359 0.3× 1.2k 1.5× 683 0.9× 177 3.4k
Simon Pernot France 25 2.2k 0.7× 1.1k 0.9× 425 0.4× 759 0.9× 609 0.8× 99 3.5k
Andréa Varga France 33 3.0k 1.0× 1.2k 1.1× 527 0.5× 1.2k 1.5× 547 0.7× 107 4.6k
Pilar García‐Alfonso Spain 26 2.6k 0.9× 891 0.8× 747 0.7× 618 0.8× 508 0.7× 148 3.1k

Countries citing papers authored by Sara De Dosso

Since Specialization
Citations

This map shows the geographic impact of Sara De Dosso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara De Dosso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara De Dosso more than expected).

Fields of papers citing papers by Sara De Dosso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara De Dosso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara De Dosso. The network helps show where Sara De Dosso may publish in the future.

Co-authorship network of co-authors of Sara De Dosso

This figure shows the co-authorship network connecting the top 25 collaborators of Sara De Dosso. A scholar is included among the top collaborators of Sara De Dosso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara De Dosso. Sara De Dosso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2025). Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. Clinical Cancer Research. 31(15). 3142–3149. 1 indexed citations
2.
Trevisi, Elena, et al.. (2024). Neo-RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review. Cancers. 16(23). 3923–3923. 3 indexed citations
3.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2024). 512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial. Annals of Oncology. 35. S432–S432. 5 indexed citations
4.
Roesel, Raffaello, Letizia Deantonio, Maria Luisa Garo, et al.. (2023). Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes. Cancers. 15(18). 4627–4627. 4 indexed citations
5.
Pavone, Giuliana, Daniel Helbling, Saskia Hussung, et al.. (2023). Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients?. Cancers. 15(17). 4398–4398. 1 indexed citations
6.
7.
Siebenhüner, Alexander, Sara De Dosso, Daniel Helbling, et al.. (2021). Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article. Oncology Research and Treatment. 44(9). 485–494. 21 indexed citations
8.
Dosso, Sara De, Alexander Siebenhüner, Thomas Winder, et al.. (2021). Treatment landscape of metastatic pancreatic cancer. Cancer Treatment Reviews. 96. 102180–102180. 120 indexed citations
9.
Siebenhüner, Alexander, Sara De Dosso, Alexander Meisel, Dorothea Wagner, & Markus Borner. (2020). Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland. Oncology Research and Treatment. 43(5). 237–244. 3 indexed citations
10.
Dosso, Sara De, Giorgio Treglia, Mariarosa Pascale, et al.. (2019). Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis. Endocrine. 64(3). 456–468. 19 indexed citations
11.
Fiedler, Walter, Herbert Stoeger, Antonella Perotti, et al.. (2018). Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open. 3(4). e000381–e000381. 14 indexed citations
12.
13.
Fazio, Nicola, Omar Abdel‐Rahman, Francesca Spada, et al.. (2014). RAF signaling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews. 40(8). 974–979. 20 indexed citations
14.
Dosso, Sara De, Renzo Boldorini, Angelica Sonzogni, et al.. (2013). ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemotherapy and Pharmacology. 72(1). 159–165. 36 indexed citations
15.
Dosso, Sara De, et al.. (2011). Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Molecular Oncology. 6(1). 15–26. 56 indexed citations
16.
Sartore‐Bianchi, Andrea, Miriam Martini, Francesca Molinari, et al.. (2009). PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. Cancer Research. 69(5). 1851–1857. 601 indexed citations breakdown →
17.
Bajetta, Emilio, Marco Platania, Laura Catena, et al.. (2007). MERKEL CELL CARCINOMAAFTER LIVER TRANSPLANTATION: A CASE REPORT. Tumori. 97(3). 323–326. 1 indexed citations
18.
Dosso, Sara De, Emilio Bajetta, Giuseppe Procopio, et al.. (2007). Pulmonary Carcinoid Tumours: Indolent but Not Benign. Oncology. 73(3-4). 162–168. 18 indexed citations
19.
Bajetta, Emilio, Laura Catena, Giuseppe Procopio, et al.. (2006). Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemotherapy and Pharmacology. 59(5). 637–642. 171 indexed citations
20.
Bajetta, Emilio, Laura Catena, Giuseppe Procopio, et al.. (2005). Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?. Annals of Oncology. 16(8). 1374–1380. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilhan Celik Breakdown of academic impact, for papers by David Tougeron Breakdown of academic impact, for papers by O. Kisker Breakdown of academic impact, for papers by Samuel J. Klempner Breakdown of academic impact, for papers by Robert Lim Breakdown of academic impact, for papers by Susana Roselló Breakdown of academic impact, for papers by Zhongwu Li Breakdown of academic impact, for papers by Simon Pernot Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Pilar García‐Alfonso
Rankless by CCL
2026